Predict your next investment

Lepu Biotechnology company logo
HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year



Series B | Alive

Total Raised


Last Raised

$185.73M | 1 yr ago

About Lepu Biotechnology

Lepu Biotechnology, established by Lepu Medical, focuses on cancer immunotherapy and has established a comprehensive industrial platform for target discovery, drug development, development, and production.

Lepu Biotechnology Headquarter Location

Room C280, Building 1 1628 Suzhao Rd., Minhang District

Shanghai, Shanghai, 201114,


+86 021 67696099

Latest Lepu Biotechnology News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Jul 3, 2019

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas 2:42 PM Share Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing investor Lepu Medical Technology (Beijing) Co. Ltd. (SZSE:300003) participated in the financing. Founded last year, Lepu has PD-1 and PD-L1 inhibitors, an oncolytic virus and multiple antibody-drug conjugates (ADCs) in Phase I-III testing. Citryll raises €15M series A from Chinese and Dutch investors  Citryll B.V. (Oss, the Netherlands) raised €15 million ($16.9 million) in a series A round from ModiQuest B.V. (Oss, the Netherlands), BOM Brabant Ventures, the BrightGene International (Hong Kong) Ltd. unit of BrightGene Bio-medical technology Co. Ltd. (Suzhou, China) and Curie Capital. The company is developing antibodies that block the formation of neutrophil extracellular traps by binding to N-terminal citrullinated epitopes in histones, which could treat autoimmune diseases such as lupus and rheumatoid arthritis. Jibeier looks to list in Shanghai  The Shanghai Stock Exchange accepted an application from Jiangsu Jibeier Pharmaceutical Co. Ltd. (Zhenjiang, China) to list on its new science and technology innovation board. The company proposed to raise up to RMB690 million ($100.2 million). The pharma develops chemical preparations and traditional Chinese medicines. Calliditas raises $22.6M  A year after going public on NASDAQ Stockholm, renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK210.3 million ($22.6 million) through the sale of 3.5 million shares at SEK60 in a private placement. Investors included BVF Partners L.P. (see "Calliditas Raises Over $70M in Swedish IPO" ). User Sign in

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lepu Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lepu Biotechnology is included in 3 Expert Collections, including Biopharmaceuticals.



5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.